Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 156-164

  Deslauriers, Jessica ^a   Larouche, Annie ^b   Sarret, Philippe ^a   Grignon, Sylvain ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Dopamine D2 receptor; GAD67; Poly I:C; Prepulse inhibition; Restraint stress

Indexed keywords

DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE 67; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID;

ACOUSTIC STARTLE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; GABAERGIC SYSTEM; GESTATION PERIOD; IMMOBILIZATION STRESS; JUVENILE ANIMAL; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SENSORY GATING; STARTLE REFLEX; WESTERN BLOTTING;

CENTRAL NERVOUS SYSTEM; CNS; D2R; DAT; DOPAMINE D2 RECEPTOR; DOPAMINE TRANSPORTER; GAD67; IL-1Β; IL-6; INTERLEUKIN-1Β; INTERLEUKIN-6; N-METHYL D-ASPARTATE; NMDA; PFC; PIC; POLY I:C; POLY I:C (POLY-INOSINIC/CYTIDYLIC ACID); PPI; PREFRONTAL CORTEX; PREPULSE INHIBITION; PREPULSE INHIBITION OF ACOUSTIC STARTLE; RESTRAINT STRESS; RS; TH; THE 67 KDA FORM OF GLUTAMIC ACID DECARBOXYLASE; TLR3; TNF-Α; TOLL-LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR-Α; TYROSINE HYDROXYLASE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMATE DECARBOXYLASE; MALE; MICE; POLY I-C; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, DOPAMINE D2; RESTRAINT, PHYSICAL; SCHIZOPHRENIA; SENSORY GATING; STRESS, PHYSIOLOGICAL;

EID: 84878851755     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.05.006     Document Type: Article

References (83)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000, 97:8104-8109.
2. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995, 52:258-266.
3. Arnsten A.F. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009, 10:410-422.
4. Asada H., Kawamura Y., Maruyama K., Kume H., Ding R.G., Kanbara N., et al. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 1997, 94:6496-6499.
5. Bayer S.A., Wills K.V., Triarhou L.C., Ghetti B. Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 1995, 105:191-199.
6. Behrens M.M., Ali S.S., Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008, 28:13957-13966.
7. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
8. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci USA 2007, 104:10164-10169.
9. Bitanihirwe B.K., Peleg-Raibstein D., Mouttet F., Feldon J., Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010, 35:2462-2478.
10. Boksa P. Maternal infection during pregnancy and schizophrenia. J Psychiatry Neurosci 2008, 33:183-185.
11. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 1999, 156:596-602.
12. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
13. Brake W.G., Zhang T.Y., Diorio J., Meaney M.J., Gratton A. Influence of early postnatal rearing conditions on mesocorticolimbic dopamine and behavioural responses to psychostimulants and stressors in adult rats. Eur J Neurosci 2004, 19:1863-1874.
14. Brown A.S., Schaefer C.A., Wyatt R.J., Goetz R., Begg M.D., Gorman J.M., et al. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 2000, 26:287-295.
15. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004, 61:774-780.
16. Deslauriers J., Lefrancois M., Larouche A., Sarret P., Grignon S. Antipsychotic-induced DRD2 upregulation and its prevention by alpha-lipoic acid in SH-SY5Y neuroblastoma cells. Synapse 2011, 65:321-331.
17. Ellenbroek B.A., Cools A.R. Early maternal deprivation and prepulse inhibition: the role of the postdeprivation environment. Pharmacol Biochem Behav 2002, 73:177-184.
18. Eranti S.V., Maccabe J.H., Bundy H., Murray R.M. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychol Med 2012, 1-13.
19. Fatemi S.H., Emamian E.S., Kist D., Sidwell R.W., Nakajima K., Akhter P., et al. Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry 1999, 4:145-154.
20. Fatemi S.H., Cuadra A.E., El-Fakahany E.E., Sidwell R.W., Thuras P. Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 2000, 11:1493-1496.
21. Fatemi S.H., Earle J., Kanodia R., Kist D., Emamian E.S., Patterson P.H., et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol 2002, 22:25-33.
22. Fatemi S.H., Araghi-Niknam M., Laurence J.A., Stary J.M., Sidwell R.W., Lee S. Glial fibrillary acidic protein and glutamic acid decarboxylase 65 and 67kDa proteins are increased in brains of neonatal BALB/c mice following viral infection in utero. Schizophr Res 2004, 69:121-123.
23. Fatemi S.H., Reutiman T.J., Folsom T.D., Huang H., Oishi K., Mori S., et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 2008, 99:56-70.
24. Fatemi S.H., Folsom T.D., Reutiman T.J., Huang H., Oishi K., Mori S. Prenatal viral infection of mice at E16 causes changes in gene expression in hippocampi of the offspring. Eur Neuropsychopharmacol 2009, 19:648-653.
25. Flaum M., Andreasen N.C. Diagnostic criteria for schizophrenia and related disorders: options for DSM-IV. Schizophr Bull 1991, 17:133-156.
26. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2008, Elsevier, Philadelphia.
27. Gogtay N., Vyas N.S., Testa R., Wood S.J., Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull 2011, 37:504-513.
28. Goldsmith S.K., Shapiro R.M., Joyce J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiatry 1997, 54:649-658.
29. Haddad J.J., Saade N.E., Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol 2002, 133:1-19.
30. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68. [image 5].
31. Harvey L., Boksa P. A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology 2012, 62:1767-1776.
32. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003, 23:6315-6326.
33. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69:776-786.
34. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
35. Kim S.T., Choi J.H., Chang J.W., Kim S.W., Hwang O. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J Neurochem 2005, 95:89-98.
36. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 2006, 26:1604-1615.
37. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001, 58:158-164.
38. Knable M.B., Barci B.M., Bartko J.J., Webster M.J., Torrey E.F. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. Mol Psychiatry 2002, 7:392-404.
39. Kramer P.F., Christensen C.H., Hazelwood L.A., Dobi A., Bock R., Sibley D.R., et al. Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice. J Neurosci 2011, 31:126-132.
40. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998, 42:211-221.
41. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996, 93:9235-9240.
42. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
43. Maynard T.M., Sikich L., Lieberman J.A., LaMantia A.S. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull 2001, 27:457-476.
44. McDonald C., Murray R.M. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 2000, 31:130-137.
45. McGlashan T.H. Early detection and intervention in schizophrenia: research. Schizophr Bull 1996, 22:327-345.
46. Meek L.R., Dittel P.L., Sheehan M.C., Chan J.Y., Kjolhaug S.R. Effects of stress during pregnancy on maternal behavior in mice. Physiol Behav 2001, 72:473-479.
47. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010, 90:285-326.
48. Meyer U., Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 2012, 62:1308-1321.
49. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005, 29:913-947.
50. Meyer U., Feldon J., Schedlowski M., Yee B.K. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun 2006, 20:378-388.
51. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 2006, 26:4752-4762.
52. Meyer U., Schwendener S., Feldon J., Yee B.K. Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res 2006, 173:243-257.
53. Meyer U., Engler A., Weber L., Schedlowski M., Feldon J. Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 2008, 154:701-709.
54. Meyer U., Nyffeler M., Schwendener S., Knuesel I., Yee B.K., Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008, 33:441-456.
55. Meyer U., Nyffeler M., Yee B.K., Knuesel I., Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008, 22:469-486.
56. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
57. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br Med J (Clin Res Ed) 1987, 295:681-682.
58. O'Callaghan E., Sham P.C., Takei N., Murray G., Glover G., Hare E.H., et al. The relationship of schizophrenic births to 16 infectious diseases. Br J Psychiatry 1994, 165:353-356.
59. Opler M.G., Susser E.S. Fetal environment and schizophrenia. Environ Health Perspect 2005, 113:1239-1242.
60. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006, 59:546-554.
61. Patin V., Lordi B., Vincent A., Thoumas J.L., Vaudry H., Caston J. Effects of prenatal stress on maternal behavior in the rat. Brain Res Dev Brain Res 2002, 139:1-8.
62. Perrone-Capano C., Tino A., di Porzio U. Target cells modulate dopamine transporter gene expression during brain development. Neuroreport 1994, 5:1145-1148.
63. Picchioni M.M., Murray R.M. Schizophrenia. BMJ 2007, 335:91-95.
64. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
65. Reynolds G.P., Zhang Z.J., Beasley C.L. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res Bull 2001, 55:579-584.
66. Seeman P., Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000, 97:7673-7675.
67. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003, 23:297-302.
68. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
69. Solberg Y., Silverman W.F., Pollack Y. Prenatal ontogeny of tyrosine hydroxylase gene expression in the rat ventral mesencephalon. Brain Res Dev Brain Res 1993, 73:91-97.
70. Suvisaari J., Haukka J., Tanskanen A., Hovi T., Lonnqvist J. Association between prenatal exposure to poliovirus infection and adult schizophrenia. Am J Psychiatry 1999, 156:1100-1102.
71. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199:331-388.
72. Tallerico T., Novak G., Liu I.S., Ulpian C., Seeman P. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res 2001, 87:160-165.
73. Torrey E.F., Rawlings R., Waldman I.N. Schizophrenic births and viral diseases in two states. Schizophr Res 1988, 1:73-77.
74. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005, 57:252-260.
75. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
76. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
77. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
78. Weinberger D.R. From neuropathology to neurodevelopment. Lancet 1995, 346:552-557.
79. Weiss I.C., Feldon J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology (Berl) 2001, 156:305-326.
80. Winter C., Djodari-Irani A., Sohr R., Morgenstern R., Feldon J., Juckel G., et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009, 12:513-524.
81. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 234:1558-1563.
82. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 2005, 39:311-323.
83. Zuckerman L., Rehavi M., Nachman R., Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003, 28:1778-1789.